在一项不受控制的II/III期试验中,针对白花粉食物过敏综合征的结构化新鲜果消费
Bettina Mueller1, Norbert Reider1, Hilal Demir2
1Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria.
概括
使用新鲜果的口服免疫疗法有效地治疗树花粉对果的食物过敏综合征. 这种治疗也提高了对其他相关食物的耐受性,提供了一个有前途的新疗法选择.
科学领域:
- 免疫学 免疫学 免疫学
- 过敏研究 研究过敏
- 食品科学 食品科学 食品科学
背景情况:
- 伯奇花粉对果的食物过敏综合征是常见的.
- 目前对于这种过敏没有标准化治疗方法.
- 这种情况显著影响患者的生活质量.
研究的目的:
- 评估用新鲜果治疗果过敏的口服治疗.
- 用各种果品种建立一个可行的治疗方案.
- 评估对树花粉食物过敏综合征 (BPFAS) 的影响.
主要方法:
- 通过皮肤刺伤测试和口腔挑测试了42种果品种的过敏性.
- 36名患者接受了12个月的口服免疫疗法,并增加了果剂量.
- 通过口服诱导,皮肤刺伤测试,IgE/IgG4水平和基细胞激活来评估疗效.
主要成果:
- 在治疗后达到一致和持久的果耐受性.
- 对其他Bet v1交叉反应性食品显著增加耐受性.
- 观察到特异性IgG4增加,特异性IgE降低到Mal d 1,以及皮肤反应性降低.
结论:
- 使用新鲜果的口服免疫疗法是对果过敏的有希望的治疗方法.
- 这种疗法也有利于对其他Bet v 1交叉反应性食物过敏的患者.
- 该研究强调了一种新的,有效的BPFAS管理方法.
相关概念视频
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Clinical Trials
8.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.6K
Allergic Reactions
28.8K
Overview
28.8K
Allergic Drug Reactions
983
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
983


